1439901-97-9

Basic information

• Product Name: ONO-4059 (hydrochloride)
• Synonyms: ONO-4059 (hydrochloride);(R)-6-amino-9-(1-but-2-ynoylpyrrolidin-3-yl)-7-(4-phenoxyphenyl)-7H-purin-8(9H)-one;ONO-4059(GS4059) hydrochloride;ONO-4059 HCl;(R)-6-amino-9-(1-(but-2-ynoyl)pyrrolidin-3-yl)-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride;(R)-6-amino-9-(1-but-2-ynoylpyrrolidin-3-yl)-7-(4-phenoxyphenyl)-7H-purin-8(9H)-one HCl salt;ONO-4059(HCl salt);Tirabrutinib (ONO-4059) HCl
• CAS NO: 1439901-97-9
• Molecular Formula: C25H23ClN6O3
• Molecular Weight: 490.94152
• EINECS: 946-274-3
• Mol File: 1439901-97-9.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ONO-4059 (hydrochloride)(CAS DataBase Reference)
• NIST Chemistry Reference: ONO-4059 (hydrochloride)(1439901-97-9)
• EPA Substance Registry System: ONO-4059 (hydrochloride)(1439901-97-9)

Safety Data

• Hazardous Substances Data: 1439901-97-9(Hazardous Substances Data)

Usage

Description

ONO-4059 (hydrochloride) is a selective and orally available Bruton’s tyrosine kinase (BTK) inhibitor, primarily developed for the treatment of B-cell lymphomas and other B-cell mediated diseases. As a key enzyme in the signaling pathway of B-cell receptors, BTK plays a crucial role in B-cell and tumor growth. ONO-4059 (hydrochloride) has shown potent and selective inhibitory effects on BTK, leading to the disruption of B-cell and tumor growth. Preclinical studies have demonstrated its promising anti-tumor activity in mouse models of B-cell lymphoma, and clinical trials are currently underway to assess its safety and efficacy in patients with B-cell lymphomas and other B-cell mediated diseases.

Uses

Used in Oncology:
ONO-4059 (hydrochloride) is used as an anticancer agent for the treatment of B-cell lymphomas and other B-cell mediated diseases. It targets and inhibits the activity of Bruton’s tyrosine kinase (BTK), a key enzyme in the signaling pathway of B-cell receptors, leading to the disruption of B-cell and tumor growth. Preclinical studies have shown its potent and selective inhibitory effects on BTK, and it has demonstrated promising anti-tumor activity in mouse models of B-cell lymphoma.
Used in Drug Development:
ONO-4059 (hydrochloride) is used as a candidate drug in the development of novel therapies for B-cell lymphomas and other B-cell mediated diseases. Its selective and potent inhibitory effects on BTK make it a promising candidate for further research and clinical trials to evaluate its safety and efficacy in patients with these conditions.
Used in Clinical Trials:
ONO-4059 (hydrochloride) is used as a test compound in ongoing clinical trials to assess its safety and efficacy in patients with B-cell lymphomas and other B-cell mediated diseases. These trials aim to determine the optimal dosage, administration, and potential side effects of the drug, as well as its overall effectiveness in treating these conditions.